Sotac Pharmaceuticals Ltd (SOTAC) — shareholding pattern, promoter holding, financials and share price
About Sotac Pharmaceuticals Ltd (SOTAC)
Sotac Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SOTAC and on the BSE under scrip code 78648. Its ISIN is INE0O2D01012.
Incorporated in 2015, Sotac Pharmaceuticals Ltd manufactures and sells a wide range of pharmaceutical products [1]
Sotac Pharmaceuticals Limited is a pharmaceutical manufacturing company in Gujarat, India, specializing in a wide range of pharmaceutical products under loan licensing or contract manufacturing partnerships.
The company has a robust portfolio covering therapeutic areas such as anti-diabetics, anti-psychotics, and antibiotics, serving a broad client base in pharmaceutical development and production.
Listed peers in Pharmaceuticals: Godavari Drugs Ltd, Pharmaids Pharmaceuticals Ltd, Krebs Biochemicals & Industries Ltd, Par Drugs & Chemicals Ltd, Denis Chem Lab Ltd, Vaishali Pharma Ltd.
Valuation & Returns
At ₹95.1 a share, Sotac Pharmaceuticals Ltd (SOTAC) was valued at a price-to-earnings ratio of 19.25x against an industry P/E of 36.41x and a price-to-book of 1.89x on a book value of ₹53.28 per share. Solomo computes return on equity of 9.79% and return on capital employed of 13.29% from filed results.
- P/E
- 19.25x
- Industry P/E
- 36.41x
- P/B
- 1.89x
- EPS (TTM)
- ₹4.21
- Book value / share
- ₹53.28
- ROE
- 9.79%
- ROCE
- 13.29%
- ROA
- 4.71%
- Debt / equity
- 0.64x
- Dividend yield
- 0.2%
- EBITDA margin
- 18.78%
- 52-week range
- ₹100 – ₹139.65
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sotac Pharmaceuticals Ltd (SOTAC) reported revenue of ₹101 crore, net profit of ₹6 crore and earnings per share of ₹5.22. That compares with revenue of ₹97 crore and net profit of ₹9 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹60 crore and net profit ₹3 crore (consolidated).
| Metric | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 49 | 77 | 104 | 97 | 101 |
| Net profit (₹ cr) | -2 | 2 | 4 | 9 | 6 |
| EPS (₹) | -10.3 | 3.58 | 3.87 | 7.27 | 5.22 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 16.81% | -5.17% | -6.59% |
| Profit growth | 31.15% | 13.13% | 159.22% |
| Stock price CAGR | - | -7% | -27% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 72.85% of Sotac Pharmaceuticals Ltd (SOTAC). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2023.
Largest disclosed public shareholders in Mar 2026: NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND 7.35%, CRAFT EMERGING MARKET FUND PCC- ELITE CAPITAL FUND 7.12%, MINERVA VENTURES FUND 1.64%, KASHYAPKUMAR RAJENDRAKUMAR MEHTA 1.54%, WALPAR NUTRITIONS LIMITED 1.49%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 72.85% | - | - | - | - |
| Sep 2025 | 72.85% | - | - | - | - |
| Mar 2025 | 72.85% | - | - | - | - |
| Sep 2024 | 72.85% | - | - | - | - |
| Mar 2024 | 72.85% | - | - | - | - |
| Sep 2023 | 72.85% | - | - | - | - |